Hanmi Pharmaceutical to Participate in World's Largest Pharmaceutical Exhibition...Promoting Global Market Competitiveness

Expanding Business Scope in the Global Healthcare Market

Hanmi Pharmaceutical announced on October 28 that it will participate in 'CPHI Worldwide 2025,' the world's largest pharmaceutical exhibition, which will be held from October 28 to 30 (local time) in Frankfurt, Germany.

Hanmi Pharmaceutical's exclusive booth at CPHI Worldwide 2025, the world's largest pharmaceutical exhibition. Hanmi Pharmaceutical

CPHI is the world's largest pharmaceutical and biotech exhibition, held annually across major European countries. This year, more than 62,000 participants from over 2,400 pharmaceutical and biotech companies representing 166 countries are expected to attend.

At this event, Hanmi Pharmaceutical will operate an exclusive booth, showcasing its self-developed blockbuster products such as Rosuzet, Amosartan, and Esomezol. The company also anticipates active global communication in the next-generation improved and combination drug sector, which is a key growth driver for Hanmi.

Additionally, Hanmi will introduce its pipeline of more than 30 innovative new drugs currently in development in the globally trending fields of obesity metabolism, oncology, and rare diseases.

Hanmi Pharmaceutical will promote its global market competitiveness, led by its self-developed biologic drug for neutropenia, Rolontis. Rolontis is the 33rd new drug developed in Korea and the first biologic drug by a Korean pharmaceutical company to receive approval from the U.S. Food and Drug Administration (FDA) in the oncology sector. Since its launch in the U.S. market in 2022 (under the local product name 'Rolbedon'), it has achieved quarterly sales of over 20 billion won, based on its excellent efficacy and safety, with cumulative sales in the U.S. market surpassing 200 billion won.

The success of Rolontis has also brought attention to the pharmaceutical manufacturing capabilities of Hanmi Group's global biopharmaceutical production base, the Pyeongtaek Bioplant. Hanmi Bioplant produces and supplies the active pharmaceutical ingredient for Rolbedon sold in the U.S. market. It has established a pharmaceutical manufacturing and quality control system that meets the latest cGMP standards, as evidenced by U.S. FDA approval.

In addition, Hanmi plans to promote its advanced large-scale manufacturing facilities (with bioreactors up to 25,000 liters), specialized personnel, and systems capable of operating them, as part of its contract development and manufacturing organization (CDMO) business activities. Unlike major domestic CDMO companies equipped with animal cell culture-based facilities, Hanmi Bioplant features manufacturing facilities that utilize microbial fermentation, enabling fast and cost-effective mass production of biopharmaceuticals made using this method as a unique strength.

A Hanmi Pharmaceutical representative stated, "By leveraging our independently developed innovative products and locally tailored strategies, we aim to expand our business scope in the global healthcare market. At the same time, we plan to actively promote the CDMO business capabilities of the Pyeongtaek Bioplant, which meets global standards, to potential clients."

This content was produced with the assistance of AI translation services.